Trending
ESWATINI, INDONESIA DEEPEN STRATEGIC TIES ON AGRICULTURE, WELLNESS INDUSTRYHungary scrambles fighter jets after Israeli passenger plane fails to contact ground controlUnhealthy air quality in California city as huge warehouse fire burns for 3rd dayLink aggregation sounded like free internet speed until I learned what it actually doesApple Watch Alternatives That Will Last For 7 Days On A ChargeDJI and Insta360 locked in global patent war over creator camera technologyShould the boost in Aussie house prices bring Kiwi homeowners hope?You think you’re cutting your power bill - but you could end up paying moreWhat To Expect? » MotorOctaneESWATINI, INDONESIA DEEPEN STRATEGIC TIES ON AGRICULTURE, WELLNESS INDUSTRYHungary scrambles fighter jets after Israeli passenger plane fails to contact ground controlUnhealthy air quality in California city as huge warehouse fire burns for 3rd dayLink aggregation sounded like free internet speed until I learned what it actually doesApple Watch Alternatives That Will Last For 7 Days On A ChargeDJI and Insta360 locked in global patent war over creator camera technologyShould the boost in Aussie house prices bring Kiwi homeowners hope?You think you’re cutting your power bill - but you could end up paying moreWhat To Expect? » MotorOctane

TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for ......

News Desk

Staff Writer

Published

Jun 13, 2026

Source

Business Wire

Analytics

0 0 0
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer

AI Insight:This approval marks a significant milestone in the treatment of PTEN-deficient prostate cancer, offering patients a targeted therapy option.

AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer. This approval is based on the results of the Phase III PROPEL trial, which demonstrated a statistically significant improvement in overall survival for patients receiving the TRUQAP® combination compared to those receiving abiraterone and prednisone alone. The PROPEL trial enrolled 806 patients with metastatic hormone-sensitive prostate cancer, of whom 23% had PTEN loss or low PTEN expression. The results of this trial highlight the importance of PTEN status in guiding treatment decisions for patients with metastatic hormone-sensitive prostate cancer and underscore the potential of TRUQAP® as a targeted therapy for this patient population.